Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria
Open Access
- 16 October 2015
- journal article
- research article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 137 (2), 474-481
- https://doi.org/10.1016/j.jaci.2015.08.023
Abstract
No abstract availableKeywords
Funding Information
- Genentech, Inc
- Novartis
This publication has 17 references indexed in Scilit:
- Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled StudyJournal of Investigative Dermatology, 2015
- The diagnosis and management of acute and chronic urticaria: 2014 updateJournal of Allergy and Clinical Immunology, 2014
- The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and updateAllergy, 2014
- Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapyJournal of Allergy and Clinical Immunology, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaNew England Journal of Medicine, 2013
- Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1Allergy, 2010
- Epidemiology of urticaria: a representative cross-sectional population surveyClinical and Experimental Dermatology, 2010
- Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidityBritish Journal of Dermatology, 2005
- A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU‐Q2oL)Allergy, 2005
- The impact of chronic urticaria on the quality of lifeBritish Journal of Dermatology, 1997